Compare IMMR & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMR | TARA |
|---|---|---|
| Founded | 1993 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.8M | 236.1M |
| IPO Year | 1999 | 2014 |
| Metric | IMMR | TARA |
|---|---|---|
| Price | $7.57 | $4.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $13.50 | ★ $24.40 |
| AVG Volume (30 Days) | 513.2K | ★ 651.1K |
| Earning Date | 04-13-2026 | 05-01-2026 |
| Dividend Yield | ★ 5.11% | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $35,013,000.00 | $2,948,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $326.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.25 | $2.97 |
| 52 Week High | $7.50 | $7.82 |
| Indicator | IMMR | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 68.37 | 45.44 |
| Support Level | $6.31 | $3.69 |
| Resistance Level | N/A | $4.23 |
| Average True Range (ATR) | 0.29 | 0.17 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 85.61 | 23.26 |
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.